Abstract 1337P
Background
Radiotherapy of the whole brain has been the basis in the treatment of non-small cell lung cancer (NSCLC) patients (pts) with brain metastasis, which can improve the rate of survival and reduce the rate of local recurrence. However, the prognosis for such patients remains poor. Previous studies had suggested that antiangiogenic drugs combined with radiation therapy might prevent the progression of disease. Apatinib is a potent antiangiogenic compound directed at the vascular endothelial growth factor receptor-2 (VEGFR-2). We conducted this trial to investigate the efficacy and safety of apatinib (antiangiogenic drugs against VEGFR-2) combined with radiation therapy for advanced NSCLC pts with brain metastasis.
Methods
This study enrolled 18 advanced NSCLC pts with brain metastasis who had failed first-line standard chemotherapy from Dec. 2017 to Oct. 2019. 18 pts all received apatinib combined with radiation therapy. Efficacy was evaluated every 6 weeks based on RECIST 1.1. This study was registered on the National Clinical Trail Registry, and the registration number was NCT03356600.
Results
77.8% (14/18) pts were available evaluated. The objective response rate (ORR) was 16.7% (2/12) and the disease control rate (DCR) was 83.3% (10/12). The most common adverse events were hypertension (44.4%, 8/18), hand-foot syndrome (22.2%, 4/18), bleeding (22.2%, 4/18) and fatigue (16.7%, 3/18). Main grade 3 or 4 toxicities were hypertension (5.6%, 1/18), hand-foot syndrome (5.6%, 1/18) and loss of appetite (5.6%, 1/18). None new adverse events occurred. Data cutoff was January 2021, the median progression-free survival, intracranial progression-free survival and overall survival were 4.4 months (95% CI 1.156-7.644), 5.6 months (95% Cl: 2.486-8.717) and 11.17 months (95% CI 5.504- 16.836).
Conclusions
Apatinib combined with radiation therapy shown a good clinical efficacy and safety in advanced NSCLC pts with brain metastasis. Patients’ quality of life and the compliance of therapy have been increased by oral drugs based on radiation therapy.
Clinical trial identification
NCT03356600.
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.